Quarterly ResultAug 7, 2026, 04:10 PM
Soligenix Halts HyBryte™ Program; Faces Going Concern Doubt & Nasdaq Delisting
AI Summary
Soligenix, Inc. reported a reduced net loss of $4.81 million for the six months ended June 30, 2026, compared to $5.65 million in the prior year, primarily due to lower R&D expenses. However, the company terminated its HyBryte™ development program in June 2026 after a futility recommendation. The company also disclosed substantial doubt about its ability to continue as a going concern and received a Nasdaq non-compliance notice for its minimum bid price.
Key Highlights
- Terminated HyBryte™ development program in June 2026 due to futility recommendation.
- Reported H1 2026 net loss of $4.81 million, an improvement from $5.65 million in H1 2025.
- Basic and diluted net loss per share was $0.37 for H1 2026, compared to $1.79 in H1 2025.
- Cash and cash equivalents increased to $9.81 million as of June 30, 2026.
- Raised $6.23 million through At Market Issuance Sales Agreement by June 30, 2026.
- Received Nasdaq non-compliance notice for $1.00 minimum bid price on June 10, 2026.
- Disclosed substantial doubt about its ability to continue as a going concern.
- R&D expenses decreased to $2.76 million for H1 2026 from $3.62 million in H1 2025.
- priority
Price Impact
More from SNGX